NDAORALTABLETPriority Review
Approved
Apr 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
155
Mechanism of Action
protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from…
Clinical Trials (5)
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Started Nov 2023
164 enrolled
Chronic Myeloid LeukemiaChronic Myeloid Leukemia, BCR/ABL-PositiveChronic Myeloid Leukemia in Remission
A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
Started Dec 2022
64 enrolled
CML
Asciminib Roll-over Study
Started Aug 2022
347 enrolled
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Started Oct 2021
406 enrolled
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Started Sep 2020
22 enrolled
Melanoma